ReviewReviews in cardiovascular medicine2026
Direct Oral Anticoagulants Versus Vitamin K Antagonists for Treatment of Left Ventricular Thrombus: A Review of Efficacy and Safety.
Review in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left ventricular thrombus (LVT) remains a critical complication of acute myocardial infarction (MI), particularly in patients with anterior ST-segment elevation myocardial infarction (STEMI) and apical dysfunction. While primary percutaneous coronary intervention (PCI) has reduced its overall incidence compared with the pre-thrombolytic era, LVT continues to pose a significant risk of systemic embolization and stroke, driven by the interplay of endothelial injury, hypercoagulability, and stasis within the aneurysmal apex. This review synthesizes current evidence on the pathophysiology, diagnosis, and management of LVT. We critically evaluate diagnostic modalities, highlighting the substantial sensitivity gap between the clinical standard, transthoracic echocardiography (TTE), and the gold standard, cardiac magnetic resonance (CMR). This discrepancy has important implications for clinical decision-making, as TTE often overestimates thrombus resolution, potentially leading to the premature cessation of therapy. Therapeutically, the landscape has shifted from the empiric use of vitamin K antagonists (VKAs) toward the adoption of direct oral anticoagulants (DOACs). Thus, we analyze recent randomized data, including the Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT) and the Rivaroxaban vs Warfarin in Acute Left Ventricular Thrombus Following Myocardial Infarction (RIVAWAR) trials, which demonstrate that DOACs are non-inferior to VKAs for embolic prevention and may offer superior resolution velocity, a crucial metric for stabilizing friable thrombi. We conclude that DOACs represent a reasonable, patient-centered alternative to warfarin. Nonetheless, future management strategies must integrate precise, serial imaging with rapid-onset anticoagulation to ensure complete histologic resolution while minimizing the hemorrhagic burden of prolonged triple antithrombotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.